Loading organizations...
Key people at MEDIPAL HOLDINGS CORPORATION.
MEDIPAL HOLDINGS CORPORATION is a leading Japanese wholesaler, distributing pharmaceuticals, medical supplies, and daily necessities. It manages a vast logistics network, procuring and delivering healthcare products, including prescription drugs, diagnostics, and animal health items. The company ensures an efficient supply chain for these goods, alongside consumer products like cosmetics.
MEDIPAL HOLDINGS CORPORATION originated from the critical need for an organized distribution system for medical and consumer goods. Though specific founders are not widely publicized, the company formed to systematically address logistical challenges in delivering vital products. This insight focused on optimizing supply channels from producers to diverse market segments.
MEDIPAL serves hospitals, clinics, pharmacies, and retailers, providing products to healthcare professionals and the public. Its vision is to advance public health and societal well-being through continually enhanced distribution infrastructure, meeting the demands of both medical and consumer sectors.
Key people at MEDIPAL HOLDINGS CORPORATION.
Medipal Holdings Corporation is a Japan-headquartered healthcare distribution group that supplies prescription drugs, OTC and daily‑use health and beauty products, animal‑health and food‑processing raw materials through a network of wholesale and related service subsidiaries, with a focus on supporting healthcare delivery and retail merchandising across Japan and select adjacent markets[2]. [1]
High‑Level Overview
Origin Story
Core Differentiators
Role in the Broader Tech / Healthcare Landscape
Quick Take & Future Outlook
Quick factual sources: Medipal’s corporate site (company overview, businesses, history and IR) and industry profiles summarizing the group’s segment structure and subsidiaries provide the basis for the above synthesis[2][1].
MEDIPAL HOLDINGS CORPORATION has 2 tracked investments across 2 companies. The latest tracked deal is $36.5M Series C in Heartseed in June 2021.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Jun 11, 2021 | Heartseed | $36.5M Series C | — | Itochu Chemical Frontier, Keio Innovation Initiative, Medical Incubator Japan, Nissay Capital, SBI Group, SMBC Capital, Sumitomo Mitsui Trust Investment, UTokyo Innovation Platform |
| May 7, 2019 | Promethera Biosciences | $44.6M Series D | Shinsei Capital Partners | Cyril Janssen, Marc Speeckaert, Olivier VAN DER Rest, Ci:z Investment, Korea Investment Partners, Mirae Asset Capital, Mitsui & CO. Global Investment, SIX Snow |